Summary Slide.png (116.66 kB)

Cost-Effectiveness Analysis of Cemiplimab Versus Chemotherapy as First-Line Treatment in Advanced NSCLC with PD-L1 Expression Levels of at Least 50%

Download (116.66 kB)
media
posted on 09.07.2021, 16:17 by Adis Rapid Journals on behalf of:, Liting Wang, Ye Peng, Xiaohui Zeng, Liubao Peng, Sini Li, Shuxia Qin, Xiaomin Wan, Chongqing Tan

Article full text


The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).

© The authors, CC-BY-NC 2021.

History